Official Korea FDA (MFDS) clinical trial phase 2B ongoing in Korea across 15 hospitals so far has shown 50-70% of test subjects showing consistent or improved cognitive function across four various standardized cognitive tests with zero reports of adverse
Aducanumab, the latest drug approved by the FDA for the treatment of Alzheimer'sis estimated to cost $56,000 annually. According to the New York Times, "There’s little evidence that the drug, Aduhelm, slows the progression of dementia, but the Food and Dr
Brain One is a naturally derived supplement made from a combination of extracts to improve memory %26 concentration. Combining the natural compounds with four-year-aged Korean ginseng boosts the immune system, enhances platelet count, and increases blood
